<![CDATA[Novo opjusterer]]>Bagsværd, Denmark, 13 April 2023 - Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and that the full-year sales and operating profit outlook at CER has been raised.

In the first three months of 2023, Novo Nordisk's sales increased by 25% and operating profit increased by 28%, both at CER. Wholesaler inventory movements in the US positively impacted sales growth.
Profit and loss (CER) First three months 2023
Sales growth 25%
Operating profit growth 28%

The sales outlook for 2023 is raised, primarily reflecting Wegovy® prescription trends in the first quarter and higher full-year expectations for sales of Wegovy® in the US. Furthermore, a second contract manufacturer is now ready to begin production, thereby increasing Wegovy® supply capacity.

The updated sales outlook also reflects higher full-year expectations for Ozempic® sales, mainly in the US, following accelerated volume growth of the GLP-1 class.
Outlook 2023 (CER) Expectations 2 February Expectations 13 April
Sales growth 13-19% 24-30%
Operating profit growth 13-19% 28-34%

Novo Nordisk's full disclosure of the financial results for the first three months of 2023 will be published on 4 May 2023.

The above expectations are based on assumptions including those described on pages 16 and 17 of the Financial report for the period 1 January 2022 to 31 December 2022 (Company Announcement No 5/2023).

The forward-looking statements on page 24 of the Financial report for the period 1 January 2022 to 31 December 2022 (Company Announcement No 5/2023) also apply to this company announcement.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information
Media:
Lars Otto Andersen-Lange
+45 3448 1298
kolg@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

]]>https://dev.proinvestor.com/forum/topic/444958/novo-opjustererRSS for NodeThu, 25 Jun 2026 17:13:57 GMTThu, 13 Apr 2023 09:48:28 GMT60<![CDATA[Reply to Novo opjusterer on Fri, 14 Apr 2023 06:09:08 GMT]]>Børshus Anbefaling efter opjustering Anbefaling før Kursmål efter opjustering Kursmål før

Jyske Bank Hold Hold 1175 1000

Danske Bank Køb Køb 1300 1175

Morningstar Sælg Sælg 860 800

BNP Paribas Exane Neutral Neutral 1105 990

Barclays Overvægt Overvægt 1200 1075

Stifel Køb Køb 1280 1205

SEB Køb Køb 1300 1250

ABG Køb Køb 1250 1150

.\˙ MarketWire

Christian Iversen Kielberg

]]>https://dev.proinvestor.com/forum/post/9482355https://dev.proinvestor.com/forum/post/9482355Fri, 14 Apr 2023 06:09:08 GMT<![CDATA[Reply to Novo opjusterer on Thu, 13 Apr 2023 12:15:13 GMT]]>Med dagens opjustering øger Novo deres vækst. Så overskuddet fordobles om 4,8 år
Manfred.

]]>https://dev.proinvestor.com/forum/post/9482351https://dev.proinvestor.com/forum/post/9482351Thu, 13 Apr 2023 12:15:13 GMT<![CDATA[Reply to Novo opjusterer on Thu, 13 Apr 2023 10:09:54 GMT]]>Kurs ultimo 938. Læg dertil aktuel forventning om vækst i overskud på 28-34%.

Ny kurs ved nogenlunde uændret P/E 1200-1257.

(Med forbehold for at en vis vækst var indregnet i kursen ved årsskiftet, for aktietilbagekøb og for valutaudsving.)

]]>https://dev.proinvestor.com/forum/post/9482352https://dev.proinvestor.com/forum/post/9482352Thu, 13 Apr 2023 10:09:54 GMT